Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,511 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Inflammatory Arthritis
Interventions: oZTEo; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Subjects
Interventions: Sativex® (Treatment A), Sativex® and fluconazole concomitantly (Treatment B); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Accidental Falls/Prevention and Control, Osteoporosis
Interventions: Deprescribing Care Model, Bone Health Service Model, Injury Prevention Service Model; Other
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 3,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions: Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis; Procedure · Other
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: New York, New York

Conditions: Focus of Study is MRI
Interventions: Not listed
Lead sponsor: Miami Cardiac and Vascular Institute; Other
Eligibility: 18 Years to 95 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Glaucoma
Interventions: SmartSystem VR Headset perimeter; Diagnostic Test
Lead sponsor: Andrew Pouw, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Naltrexone, Methylphenidate Abuse
Interventions: Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421; Drug
Lead sponsor: Avekshan LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions: RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Parkinson Disease (PD)
Interventions: Overactive bladder antimuscarinic deprescribing; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast MRI
Interventions: Standard of care contrast agent, provided in split dose, Breast MRI; Drug · Diagnostic Test
Lead sponsor: Manojkumar Saranathan; Other
Eligibility: 30 Years to 89 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Interventions: Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: TBP-PI-HBr; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anterior Segment of Eye
Interventions: Lightfield Medical Vscan001 Automated Slit-lamp Camera; Device
Lead sponsor: Lightfield Medical; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Golden Valley, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: suspension IR, CR 1, CR 2, CR 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cytomegalovirus (CMV)
Interventions: Digoxin, Maribavir, Dextromethorphan; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Prevention
Interventions: HIV Podcast for Heterosexual African American Adults; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method; Drug · Other · Genetic
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 17
States / cities: Alhambra, California • Fullerton, California • Long Beach, California + 12 more

Conditions: Drug Interaction
Interventions: Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Psoriasis
Interventions: BMS-986165, Cyclosporine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic
Interventions: Cardiac and Brain MRI; Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.

Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

Non-Enhanced Magnetic Resonance Angiography With the t-SLIP Technique

SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter

Study for Naltrexone on the Abuse Potential of Methylphenidate

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

Low-dose Imaging TechniquE in Breast MRI

Regional Phenotyping of CF and Non-CF Bronchiectasis

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Feasibility Study of a Novel Automated Slit Lamp Camera (Lightfield Medical Ophthalmic Camera Model Vscan001)

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

Study of SHP620 (Maribavir) in Healthy Adults

Podcasting HIV Prevention Within African American Communities

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study